Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of anaprazole-based bismuth quadruple therapy for Helicobacter pylori eradication
CTR20261984Phase 3Active
- Sponsor
- Xuanzhu Biopharmaceutical
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of anaprazole sodium in Helicobacter pylori infection, sponsored by Xuanzhu Biopharmaceutical. Started May 2026; status: active.
02
Drugs
anaprazole sodium
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on CTR20261984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261984.